This concept has been widely used in clinical practice, and currently, low-dose IL-2 is being used for the treatment of diseases, including graft-versus-host disease (GVHD), TID, hepatitis C virus-induced vasculitis, spinal arthropathy, and SLE [24, 38]. This evidence concerns the gene IL2 and systemic lupus erythematosus.